ArticleJournal of pharmacokinetics and pharmacodynamics2026
Diffusion models for virtual populations and pharmacometric simulations.
Article in Journal of pharmacokinetics and pharmacodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Copula-Based Framework for Modeling Dependency Structures in PBPK Virtual Populations: A Chinese Adult Case Study.Pharmaceutical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate diffusion model-based artificial intelligence approaches for generating virtual populations with physiological determinants of drug dosing (PDODD) and pharmacokinetic (PK) profiles. A denoising diffusion probabilistic model (DDPM) was applied to a 31-variable dataset of PDODD covariates (18 continuous, 13 binary) from the National Health and Nutrition Examination Survey and compared to a tabular variational autoencoder (TVAE). For nivolumab PK data (12,000 patients, 13 time points, 5 covariates), sequence-based diffusion model (SDM) and a time-aware diffusion model (TDM) with temporal self-attention were evaluated. The predictive performance of the TDM was evaluated by imputing masked time points. All models were trained and tested on 80%:20% partitions of the data using univariate, bivariate, and multivariate distributional similarity metrics. The diffusion model satisfactorily approximated the univariate distributions of continuous PDODD biomarkers (mean Kolmogorov-Smirnov D-statistic, KSD = 0.014), disease status frequencies (mean absolute error, MAE = 0.31%), and preserved bivariate correlations (MAE = 0.033). DDPM outperformed TVAE for categorical variables (0.31% vs. 1.07% MAE) and correlation (0.033 vs. 0.091 MAE). For nivolumab PK, SDM has KSD of 0.047 and a relative error of 1.36%. TDM accurately imputed missing PK timepoints (KSD = 0.014), reconstructing masked Day 1, Peak concentration (Cmax) Dose-9, and Terminal phase concentrations with MAE of 0.43%, 0.25%, and 0.76%, and correlations ≥ 0.999. Diffusion models demonstrated strong performance in generating cross-sectional PK covariate data and longitudinal PK profiles, capturing complex distributional and temporal dependencies. Diffusion-based approaches provide a flexible and robust framework for virtual simulations in pharmacometrics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.